Multifunctional nanoscale platforms for targeting of the cancer cell immortality spectrum.
暂无分享,去创建一个
Ram Sasisekharan | Venkataramanan Soundararajan | Kenneth Warnock | R. Sasisekharan | V. Soundararajan | Ken Warnock
[1] M. Nugent,et al. Heparinase treatment of bovine smooth muscle cells inhibits fibroblast growth factor-2 binding to fibroblast growth factor receptor but not FGF-2 mediated cellular proliferation , 2004, Angiogenesis.
[2] P. Sorger,et al. Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.
[3] Robert Langer,et al. Visual Evidence of Acidic Environment Within Degrading Poly(lactic-co-glycolic acid) (PLGA) Microspheres , 2004, Pharmaceutical Research.
[4] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[5] Michael L Klein,et al. Emerging Applications of Polymersomes in Delivery: from Molecular Dynamics to Shrinkage of Tumors. , 2007, Progress in polymer science.
[6] John C. Bischof,et al. Enhancement of tumor thermal therapy using gold nanoparticle–assisted tumor necrosis factor-α delivery , 2006, Molecular Cancer Therapeutics.
[7] R. Bellamkonda,et al. Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[8] Robert Langer,et al. Multifunctional nanoparticles for prostate cancer therapy , 2009, Expert review of anticancer therapy.
[9] May D. Wang,et al. Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment. , 2009, Trends in biotechnology.
[10] C. Lieber,et al. Nanowire Nanosensors for Highly Sensitive and Selective Detection of Biological and Chemical Species , 2001, Science.
[11] S. Friedlander,et al. Dynamics of Chain Aggregates of Carbon Nanoparticles in Isolation and in Polymer Films: Implications for Nanocomposite Materials , 2004 .
[12] T. Park,et al. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[13] A. Sarasin,et al. An overview of the mechanisms of mutagenesis and carcinogenesis. , 2003, Mutation research.
[14] Philip S Low,et al. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. , 2005, Journal of pharmaceutical sciences.
[15] Z. Duan,et al. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. , 2003, Current cancer drug targets.
[16] C. Astete,et al. Synthesis and characterization of PLGA nanoparticles , 2006, Journal of biomaterials science. Polymer edition.
[17] A. Göpferich,et al. Erosion of composite polymer matrices. , 1997, Biomaterials.
[18] J. Siepmann,et al. Mathematical modeling of bioerodible, polymeric drug delivery systems. , 2001, Advanced drug delivery reviews.
[19] Raul E Cachau,et al. In-silico nanobio-design. A new frontier in computational biology. , 2007, Current topics in medicinal chemistry.
[20] C. Berkland,et al. Combination Chemotherapeutic Dry Powder Aerosols via Controlled Nanoparticle Agglomeration , 2009, Pharmaceutical Research.
[21] Robert Langer,et al. Advancing the field of drug delivery: taking aim at cancer. , 2003, Cancer cell.
[22] W. Greco,et al. The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.
[23] Chad A Mirkin,et al. Nanostructures in biodiagnostics. , 2005, Chemical reviews.
[24] Shiladitya Sengupta,et al. A dual‐color fluorescence imaging‐based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[25] B. Stockwell,et al. Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.
[26] J. Lehár,et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.
[27] Sunita Yadav,et al. Multi-functional nanocarriers to overcome tumor drug resistance. , 2008, Cancer treatment reviews.
[28] M. Blasco. Telomeres and human disease: ageing, cancer and beyond , 2005, Nature Reviews Genetics.
[29] S. Schwendeman,et al. Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide) , 2000, Nature Biotechnology.
[30] K. Dixon,et al. Genetic alterations and DNA repair in human carcinogenesis. , 2004, Seminars in cancer biology.
[31] R. Leonard,et al. Capecitabine and Docetaxel Combination for the Treatment of Breast Cancer , 2008, Women's health.
[32] C. Larabell,et al. Quantum dots as cellular probes. , 2005, Annual review of biomedical engineering.
[33] R. Kerbel,et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[34] Gengfeng Zheng,et al. Multiplexed electrical detection of cancer markers with nanowire sensor arrays , 2005, Nature Biotechnology.
[35] J. Groten,et al. Toxicology of simple and complex mixtures. , 2001, Trends in pharmacological sciences.
[36] Robert Langer,et al. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. , 2007, Nanomedicine.
[37] T Görner,et al. Lidocaine loaded biodegradable nanospheres. II. Modelling of drug release. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[38] Rong Zhou,et al. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. , 2004, Academic radiology.
[39] R. Sasisekharan,et al. Exploiting nanotechnology to target cancer , 2007, British Journal of Cancer.
[40] M. Prabhakaran,et al. Nanotechnology for nanomedicine and delivery of drugs. , 2008, Current pharmaceutical design.
[41] Mansoor M Amiji,et al. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery , 2006, Expert opinion on drug delivery.
[42] R. C. Dutta. Drug carriers in pharmaceutical design: promises and progress. , 2007, Current pharmaceutical design.
[43] R. Jain,et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. , 2000, Cancer research.
[44] Robert Langer,et al. Impact of nanotechnology on drug delivery. , 2009, ACS nano.
[45] A. Knudson,et al. Two genetic hits (more or less) to cancer , 2001, Nature Reviews Cancer.
[46] E. K. Park,et al. Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. , 2004, Biomaterials.
[47] R. Langer,et al. [46] Immobilized heparin lyase system for blood deheparinization , 1988 .
[48] Robert Langer,et al. Multi-pulse drug delivery from a resorbable polymeric microchip device , 2003, Nature materials.
[49] David M. Livingston,et al. Cancer: Crossing over to drug resistance , 2008, Nature.
[50] Amanda Paulovich,et al. Cancer biomarkers: a systems approach , 2006, Nature Biotechnology.
[51] J. McNamara,et al. Cell-specific aptamers for targeted therapies. , 2009, Methods in molecular biology.
[52] K Zygourakis,et al. Computer-aided design of bioerodible devices with optimal release characteristics: a cellular automata approach. , 1996, Biomaterials.
[53] R. Langer,et al. Nanomedicine: developing smarter therapeutic and diagnostic modalities. , 2006, Advanced drug delivery reviews.
[54] Zachary Shriver,et al. Roles of heparan-sulphate glycosaminoglycans in cancer , 2002, Nature Reviews Cancer.
[55] G. Robertson,et al. Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development , 2008, Clinical Cancer Research.
[56] J. Post,et al. Quantum dot ligands provide new insights into erbB/HER receptor–mediated signal transduction , 2004, Nature Biotechnology.
[57] Indu Bala,et al. PLGA nanoparticles in drug delivery: the state of the art. , 2004, Critical reviews in therapeutic drug carrier systems.
[58] Kewal K. Jain. Ethical, Safety, and Regulatory Issues of Nanomedicine , 2008 .
[59] P. Lin,et al. Nanotechnology for antiangiogenic cancer therapy. , 2006, Nanomedicine.
[60] Omid C Farokhzad,et al. Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates , 2007, ChemMedChem.
[61] Sophie Lanone,et al. Potential uses of carbon nanotubes in the medical field: how worried should patients be? , 2007, Nanomedicine.
[62] S. Ramalingam,et al. Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. , 2009, Clinical lung cancer.
[63] Harald zur Hausen,et al. Infections Causing Human Cancer: ZUR HAUSEN:INFECT&CANCER O-BK , 2006 .
[64] Ting-Chao Chou,et al. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.
[65] J. Elmore,et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. , 1998, The New England journal of medicine.
[66] Chryso Kanthou,et al. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies , 2009, International journal of experimental pathology.
[67] Shantesh Hede,et al. "Nano": the new nemesis of cancer. , 2006, Journal of cancer research and therapeutics.
[68] M. Bruchez,et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots , 2003, Nature Biotechnology.
[69] P Wust,et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial , 2007, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[70] A. Annapragada,et al. Triggered release of ciprofloxacin from nanostructured agglomerated vesicles , 2007, International journal of nanomedicine.
[71] J. Huwyler,et al. Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[72] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[73] R. Sasisekharan,et al. A simple assay to probe disease-associated enzyme activity using glycosaminoglycan-assisted synthesized gold nanoparticles. , 2008, Organic & biomolecular chemistry.
[74] Robert Langer,et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.
[75] Shuming Nie,et al. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. , 2009, Current drug discovery technologies.
[76] Robert S. Kerbel,et al. The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.
[77] F. Zhan,et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. , 2003, Cancer research.
[78] Z. Duan,et al. Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles , 2008, Clinical Cancer Research.
[79] V. Ling. Multidrug resistance: molecular mechanisms and clinical relevance , 1997, Cancer Chemotherapy and Pharmacology.
[80] Corey Nislow,et al. Combination chemical genetics. , 2008, Nature chemical biology.
[81] R. Stafford,et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[82] A. Krishan,et al. Monitoring of cellular resistance to cancer chemotherapy. , 2002, Hematology/oncology clinics of North America.
[83] Shiladitya Sengupta,et al. Nitric oxide modulates hepatocyte growth factor/scatter factor-induced angiogenesis , 2004, Angiogenesis.
[84] T. Haller,et al. A voxel-based Monte Carlo model of drug release from bulk eroding nanoparticles. , 2010, Journal of nanoscience and nanotechnology.
[85] M. Alonso,et al. Design and characterisation of new nanoparticulate polymer blends for drug delivery , 2004, Journal of biomaterials science. Polymer edition.
[86] C Malvy,et al. Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[87] J. Folkman,et al. Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.
[88] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[89] Nelson Durán,et al. New aspects of nanopharmaceutical delivery systems. , 2008, Journal of nanoscience and nanotechnology.
[90] J. Rojo,et al. Gold Glyconanoparticles as Water-Soluble Polyvalent Models To Study Carbohydrate Interactions. , 2001, Angewandte Chemie.
[91] Robert Langer,et al. Modeling of polymer erosion in three dimensions: Rotationally symmetric devices , 1995 .
[92] Shiladitya Sengupta,et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system , 2005, Nature.
[93] L. Eaton. World cancer rates set to double by 2020 , 2003, BMJ : British Medical Journal.
[94] J. Karp,et al. Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .
[95] D. Tripathy. Overcoming Fundamental Challenges in Systemic Therapy for Breast Cancer , 2009 .
[96] S. Glotzer,et al. Computer simulations of block copolymer tethered nanoparticle self-assembly. , 2006, The Journal of chemical physics.
[97] Sanjiv S Gambhir,et al. Drug delivery: keeping tabs on nanocarriers. , 2007, Nature nanotechnology.
[98] B. Kamen,et al. Receptor-mediated folate accumulation is regulated by the cellular folate content. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[99] M. Delano,et al. Emerging implications of nanotechnology on cancer diagnostics and therapeutics , 2006, Cancer.
[100] C. Mohanty,et al. Ligand-based targeted therapy for cancer tissue , 2009, Expert opinion on drug delivery.
[101] P. Low,et al. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[102] Masato Takahashi,et al. N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma , 2007, Molecular Cancer.
[103] Lawrence Kulinsky,et al. Development of integrated protection for a miniaturized drug delivery system , 2007 .
[104] A. Saxena,et al. Efficient computation of the structural phase behavior of block copolymers. , 2002, Physical review. E, Statistical, nonlinear, and soft matter physics.
[105] R. Sasisekharan,et al. On the regulation of fibroblast growth factor activity by heparin-like glycosaminoglycans , 2004, Angiogenesis.
[106] Arie E. Kaufman,et al. The CUBE workstation —a 3-D voxel-based graphics environment , 1988, The Visual Computer.
[107] Hedi Mattoussi,et al. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy , 2004, Nature Medicine.
[108] L R Coney,et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. , 1992, Cancer research.
[109] M. Gottesman. Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.
[110] Tejraj M Aminabhavi,et al. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. , 2008, Journal of controlled release : official journal of the Controlled Release Society.